Abeta beta-Hairpin Peptides and Oligomers as Treatments for Alzheimer's Disease
Funded at University of California-Irvine · NIH-11447956 · Data updated 2026-11-12
Aims to develop vaccines and antibodies that target early amyloid beta shapes to slow Alzheimer’s in people who have or are at risk for the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | September 15, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $739,365 |
| NIH project number | 1R01AG098878-01A1 |
| Project ID | NIH-11447956 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Alzheimer’s disease or related cognitive impairments, and individuals at risk due to family history or biomarker evidence, who could participate in vaccine or antibody studies.
✕Less likely to help
Some participants may not experience cognitive benefit or could experience immune-related side effects.
What this research studies
This project focuses on creating vaccines and antibodies that recognize early, non-fibrillar forms of amyloid beta implicated in Alzheimer's. By using structure-guided designs, it seeks to engage those early Aβ shapes to potentially reduce brain damage and slow cognitive decline. The work involves both active vaccines that prompt a person’s own immune system and passive antibodies given directly, with attention to safety and avoiding adverse imaging effects. If successful, the approach could add a preventive or disease-modifying option for patients with Alzheimer’s disease or related conditions.
Why it matters
Potential benefit: If successful, it could slow cognitive decline and modify disease progression by targeting early Aβ forms.
How similar studies have gone: There is prior evidence that anti-amyloid therapies can alter disease trajectory, but results have been variable and safety concerns exist with certain approaches.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Kreutzer, Adam George — University of California-Irvine
- Study coordinator: Kreutzer, Adam George
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.